CMAAO Coronavirus Facts and Myth Buster: Vaccine Tracker

With input from Dr Monica Vasudev

1177 COVID-19 vaccine tracker

1. To date, only two coronavirus vaccines have been approved. Sputnik V developed by the Gamaleya Research Institute in Moscow was approved by the Ministry of Health of the Russian Federation on August 11.
2. A second vaccine in Russia, named EpiVacCorona, has also received regulatory approval, also without entering Phase 3 clinical trials.

 

	Candidate	Type of vaccine	Sponsor	Phase of trial
	AZD1222	Replication-deficient viral vector vaccine (chimpanzee adenovirus)	The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India	Phase 3
	BNT162	mRNA-based vaccine	Pfizer, BioNTech	Phase 3
	mRNA-1273	mRNA-based vaccine	Moderna	Phase 3
	Ad5-nCoV	Recombinant vaccine (adenovirus type 5 vector)	CanSino Biologics	Phase 3
	CoronaVac	Inactivated vaccine (formalin with alum adjuvant)	Sinovac	Phase 3
	Covaxin	Inactivated vaccine	Bharat Biotech; National Institute of Virology	Phase 3
	JNJ-78436735	Non-replicating viral vector	Johnson & Johnson	Phase 3
	Name not announced	Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 3
	NVX-CoV2373	Nanoparticle vaccine	Novavax	Phase 3
	Sputnik V	Non-replicating viral vector	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Phase 3
BCG vaccine	Live-attenuated vaccine	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Phase 2/3
INO-4800	DNA vaccine (plasmid)	Inovio Pharmaceuticals	Phase 2/3		Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia
VIR-7831	Plant-based adjuvant vaccine	Medicago; GSK; Dynavax	Phase 2/3		Medicago
Name not announced	Recombinant vaccine	Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences	Phase 2		Various
ZyCoV-D	DNA vaccine (plasmid)	Zydus Cadila	Phase 2		Zydus Cadila
No name announced	Adjuvanted protein subunit vaccine		Phase 1/2
AG0301-COVID19	DNA vaccine	AnGes, Inc.	Phase 1/2	AnGes, Inc.; Japan Agency for Medical Research and Development
BBIBP-CorV	Inactivated vaccine	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 1/2	Henan Provincial Center for Disease Control and Prevention
EpiVacCorona	Peptide vaccine	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology	Phase 1/2		Federal Budgetary Research Institution State Research Center of Virology and Biotechnology
GX-19	DNA vaccine	Genexine	Phase 1/2
LNP-nCoVsaRNA	Self-amplifying RNA vaccine	Imperial College London	Phase 1/2
ARCT-021 (LUNAR-COV19)	Self-replicating RNA vaccine	Arcturus Therapeutics and Duke-NUS Medical School	Phase 1/2
Name not announced	Protein subunit vaccine	Sanofi; GlaxoSmithKline	Phase 1/2
No name announced	Inactivated vaccine	Chinese Academy of Medical Sciences, Institute of Medical Biology	Phase 1/2
AdimrSC-2f	Protein subunit vaccine	Adimmune	Phase 1
bacTRL-Spike	Monovalent oral vaccine (bifidobacteria)	Symvivo	Phase 1
COVAX-19	Monovalent recombinant protein vaccine	Vaxine Pty Ltd.	Phase 1
CVnCoV	mRNA-based vaccine	CureVac	Phase 1
DelNS1-2019-nCoV-RBD-OPT1	Replicating viral vector	Xiamen University, Beijing Wantai Biological Pharmacy	Phase 1
GRAd-COV2	Adenovirus-based vaccine	ReiThera; Leukocare; Univercells	Phase 1
UQ-CSL V451	Protein subunit vaccine	CSL; The University of Queensland	Phase 1
No name announced	Adenovirus-based vaccine	ImmunityBio; NantKwest	Phase 1	Phase 1
SCB-2019	Protein subunit vaccine	GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPI	Phase 1	Linear Clinical Research (Australia)
UB-612	Multitope peptide-based vaccine	COVAXX	Phase 1	United Biomedical Inc. (UBI)
V590	Recombinant vaccine (vesicular stomatitis virus)	Merck; IAVI	Phase 1
V591	Measles vector vaccine	University of Pittsburgh’s Center for Vaccine Research	Phase 1	University of Pittsburgh; Themis Biosciences; Institut Pasteur
VXA-CoV2-1	Recombinant vaccine (adenovirus type 5 vector)	Vaxart	Phase 1	Vaxart
AAVCOVID	Gene-based vaccine	Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania	Pre-clinical
AdCOVID	Intranasal vaccine	Altimmune	Pre-clinical	University of Alabama at Birmingham
ChAd-SARS-CoV-2-S	Adenovirus-based vaccine	Washington University School of Medicine in St. Louis	Pre-clinical	Washington University School of Medicine in St. Louis
HaloVax	Self-assembling vaccine	Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc.	Pre-clinical
HDT-301	RNA vaccine	University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp	Pre-clinical
LineaDNA	DNA vaccine	Takis Biotech	Pre-clinical
MRT5500	Recombinant vaccine	Sanofi, Translate Bio	Pre-clinical
No name announced	Ii-Key peptide COVID-19 vaccine	Generex Biotechnology	Pre-clinical
No name announced	Protein subunit vaccine	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	Pre-clinical
No name announced	mRNA-based vaccine	Chulalongkorn University’s Center of Excellence in Vaccine Research and Development	Pre-clinical
No name announced	gp96-based vaccine	Heat Biologics	Pre-clinical
No name announced	Inactivated vaccine	Shenzhen Kangtai Biological Products	Pre-clinical
PittCoVacc	Recombinant protein subunit vaccine (delivered through microneedle array)	UPMC/University of Pittsburgh School of Medicine	Pre-clinical
T-COVIDTM	Intranasal vaccine	Altimmune	Pre-clinical

 

[Source: raps.org]

 

Dr KK Aggarwal

President CMAAO, HCFI and Past National President IMA